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UroguanylinThe natural hormone uroguanylin regulates intestinal ﬂuid homeostasis and bowel function through acti-
vation of guanylate cyclase-C (GC-C), resulting in increased intracellular cyclic guanosine-30,50-mono-
phosphate (cGMP). We report the effects of uroguanylin-mediated activation of the GC-C/cGMP
pathway in vitro on extracellular cGMP transport and in vivo in rat models of inﬂammation- and
stress-induced visceral hypersensitivity. In vitro exposure of intestinal Caco-2 cells to uroguanylin stim-
ulated bidirectional, active extracellular transport of cGMP into luminal and basolateral spaces. cGMP
transport was signiﬁcantly and concentration dependently decreased by probenecid, an inhibitor of
cGMP efﬂux pumps. In ex vivo Ussing chamber assays, uroguanylin stimulated cGMP secretion from
the basolateral side of rat colonic epithelium into the submucosal space. In a rat model of trinitrobenzene
sulfonic acid (TNBS)-induced visceral hypersensitivity, orally administered uroguanylin increased colonic
thresholds required to elicit abdominal contractions in response to colorectal distension (CRD). Oral
administration of cGMP mimicked the antihyperalgesic effects of uroguanylin, signiﬁcantly decreasing
TNBS- and restraint stress–induced visceromotor response to graded CRD in rats. The antihyperalgesic
effects of cGMP were not associated with increased colonic spasmolytic activity, but were linked to sig-
niﬁcantly decreased ﬁring rates of TNBS-sensitized colonic afferents in rats in response to mechanical
stimuli. In conclusion, these data suggest that the continuous activation of the GC-C/cGMP pathway along
the intestinal tract by the endogenous hormones guanylin and uroguanylin results in signiﬁcant reduc-
tion of gastrointestinal pain. Extracellular cGMP produced on activation of GC-C is the primary mediator
in this process via modulation of sensory afferent activity.
 2013 International Association for the Study of Pain. Published by Elsevier B.V. Open access under 1. Introduction
The endogenous hormones guanylin and uroguanylin are cyclic
guanosine-30,50-monophosphate (cGMP)–regulating signaling pep-
tides involved in intestinal ﬂuid homeostasis and bowel function of
the gastrointestinal tract [17,23,25]. Their effects occur through
activation of guanylate cyclase-C (GC-C), a type I transmembrane
receptor expressed predominantly on the apical surface of intesti-
nal epithelial cells [9,29,47]. Receptor activation by selective GC-C
agonists such as uroguanylin results in increased intracellularconcentrations of the second messenger cGMP [17,39], which
mediates its biological effects. Recently, it was shown that the
synthetic peptide linaclotide, closely related to the endogenous
hormones guanylin and uroguanylin, also increased intracellular
concentrations of cGMP, resulting in augmented intestinal ﬂuid
secretion and accelerated transit in rodents [7,8]. In addition, lin-
aclotide reduced colonic hypersensitivity in several rodent models
of postinﬂammatory and stress-induced visceral hypersensitivity,
in a GC-C–dependent manner, a mechanism not previously linked
to the GC-C/cGMP pathway [16]. Moreover, clinical studies have
also documented the beneﬁt of GC-C agonists in improving pain
in conditions like irritable bowel syndrome (IBS) with constipation
(IBS-C). IBS-C patients treated with linaclotide, a drug approved by
the FDA for the treatment of patients with IBS-C and chronic
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cally meaningful improvements in abdominal pain compared with
placebo-treated patients, as well as an improvement in bowel hab-
its [13,22,42]. It has been hypothesized that the analgesic effects of
linaclotide may also be mediated by extracellular cGMP.
An increase in intracellular cGMP is known to modulate a
variety of cellular processes, and its well-characterized intracellu-
lar effects are primarily mediated through interaction with 3
groups of target proteins: cGMP-dependent protein kinases, cyclic
nucleotide–gated ion channels, and cGMP-regulated phosphodies-
terases [46]. In contrast, the effects of cGMP after transport out of
intestinal epithelial cells after activation of GC-C remain unknown.
It is known that cGMP can be actively transported out of cells
through membrane-bound transport proteins [44]. In the central
nervous system (CNS), activation of glutamate receptors have been
shown to increase intracellular cGMP and to induce cGMP release
in cultured cerebellar neurons or in cerebellar slices [30,33,51].
Several studies that investigated the effects of extracellular cGMP
on neuronal cells showed direct inhibitory effects of cGMP on
CNS neurons resulting in reduced excitability and inhibition of
neurotransmitter release, suggesting a role for cGMP in processes
modulating neuronal activity [12,30,40].
In this study, we investigated whether uroguanylin, through
activation of the GC-C/cGMP pathway, elicits analgesic effects in
models of gastrointestinal pain and whether these analgesic effects
could be mimicked by exogenous cGMP, thus suggesting a novel
role for the GC-C/cGMP pathway in modulating gastrointestinal
sensory signaling.
2. Methods
2.1. Animals
Male and female Sprague-Dawley and Wistar rats, respectively,
were obtained from Elevage Janvier S.A. (Le Genest St. Isle, France)
to measure visceromotor (abdominal contractions) responses in
rats to colorectal distension (CRD) in postinﬂammatory TNBS-in-
duced visceral hypersensitivity and after partial restraint stress.
For colonic afferent responses to colonic distension after TNBS-in-
duced colitis, female Sprague-Dawley rats were obtained from Hill-
top Lab Animals (Scottsdale, PA). All animal studies were approved
by institutional committees based on approved guidelines: Animal
Care and Use Committee of the Institut National de la Recherche
Agronomique, University of Pittsburgh Institutional Animal Care
and Use Committee in accordance with the standards set by the
Animal Welfare Act and the National Institutes of Health (Guide
for the Care and Use of Laboratory Animals), the Committee for Re-
search and Ethical Issue of the IASP (1983) and the European
Guidelines 2010/63/UE, and the Ironwood Pharmaceuticals Institu-
tional Animal Care and Use Committee.
2.2. Reagents
Caco-2 cells were obtained from American Type Culture Collec-
tion (Manassas, VA). Probenecid, p-nitrophenyl-N-acetyl-b-D-glu-
cosamide, 8-bromo-cGMP, and cGMP were obtained from Sigma
(St. Louis, MO) and acetylcholine (Ach) from MP Biomedicals (San-
ta Ana, CA). Human uroguanylin-A (uroguanylin) was obtained
from American Peptide (Sunnyvale, CA).
2.3. Caco-2 cell differentiation
Caco-2 cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium supplemented with 10% fetal bovine serum and
2 mmol/L glutamine in a humidiﬁed atmosphere containing 5%
CO2 in air at 37C for 21 days on 24-well collagen-coated insertplates (BD Biosciences, Bedford, MA). Caco-2 cell monolayer integ-
rity was conﬁrmed by measurement of transepithelial electrical
resistance using an epithelial tissue volt-ohm meter (SYS-WVOM
with STX2 electrode; World Precision Instruments Inc., Sarasota,
FL), and monolayers with resistance values of >250Xcm2 were
considered completely conﬂuent and used in the transport exper-
iments. Furthermore, apical-to-basolateral permeability of manni-
tol was measured to monitor the integrity of tight junctions and
was compared with the permeability of propranolol, a highly
monolayer-permeable drug.
2.4. Measurement of intracellular and extracellular concentrations of
cGMP
Conﬂuent (day 21) Caco-2 cell monolayers were washed twice
with prewarmed transport buffer (Hanks’ balanced salt solution
supplemented with 15 mmol/L glucose and 10 mmol/L N-hydroxy-
ethylpiperazine-N0-2-ethanesulfonic acid (HEPES), pH 7.0). Trans-
port buffer containing either vehicle (1% dimethyl sulfoxide) or
probenecid (0.5, 2 mmol/L) in vehicle was then added to both the
apical and basolateral chambers and incubated for 15 minutes at
37C. After incubation for 15 minutes, the transport buffer was
aspirated, and the apical (volume: 0.3 mL) and basolateral cham-
bers (volume: 1 mL) of triplicate wells were treated with vehicle,
uroguanylin (1 lmol/L), or uroguanylin (1 lmol/L) plus 0.5 and
2 mmol/L of probenecid and incubated at 37C for 60 minutes.
After the 60-minute incubation period, 0.2-mL aliquots from both
the apical and basolateral chambers were collected, and the con-
centration of cGMP in each chamber was determined by liquid
chromatography coupled to mass spectrometry (LC/MS/MS) analy-
sis. To determine the concentration of intracellular cGMP, the
Caco-2 cells were lysed in 0.1 mL of 0.1 M hydrochloric acid at
room temperature for 15 minutes, followed by centrifugation
(3200 rpm, 15 minutes) to pellet cell debris. The supernatants
(90 lL) were transferred to 96-well plates and neutralized (pH
7.0) with 90 lL of 1 mol/L ammonium acetate, and analyzed by
LC/MS/MS. A cGMP standard curve (10 nmol/L–10 lmol/L) was
prepared in transport buffer (pH 7.0) or 0.1 mol/L hydrochloric
acid, neutralized with an equal volume of 1 mol/L ammonium
acetate. The data were processed using LCquan 2.5.6 software
(Thermo-Fisher Scientiﬁc, Pittsburgh, PA). Analyte peak areas were
used to generate a 1/x2-weighted linear calibration curve, which
was used to extrapolate the cGMP concentration in each sample.
2.5. Expression of GC-C, guanylin and uroguanylin, and cGMP
transporters multidrug resistance proteins 4 and 5, and organic anion
transporter 2 in Caco-2 cells and in rat tissue panel
Rat tissue total RNA and RNA from Caco-2 cells was extracted
using Trizol (Life Technologies, Grand Island, NY) and further puri-
ﬁed with the RNeasy Mini Kit (Qiagen, Valencia, CA). cDNAs were
synthesized using a high-capacity cDNA reverse-transcription kit
(Life Technologies). cDNA 500 ng was used for TaqMan quantita-
tive real-time polymerase chain reaction gene expression analysis.
Human and rat TaqMan cDNA probes speciﬁc for GC-C, guanylin,
uroguanylin, multidrug-resistance proteins (MRP) 4 and 5, organic
anion transporter (OAT) 2, and glyceraldehyde 3-phosphate dehy-
drogenase (housekeeping gene, control) were obtained from Life
Technologies. The 2DDCt method was used to calculate relative
mRNA expression [31].
2.6. Preparation of rat peritoneal mast cells
Mast cells from Sprague-Dawley rats were obtained by
peritoneal lavage of adult animals with 30 to 35 mL of Tyrode’s
buffer (137 mmol/L NaCl, 2.7 mmol/L KCl, 0.4 mmol/L NaH2PO4,
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HEPES, pH 7.2) containing 0.1% BSA (fatty acid–free bovine serum
albumin). Puriﬁcation of peritoneal mast cells was performed
according to the method previously described by Lee et al. [27].
Brieﬂy, peritoneal cells (6–10  107 cells) were suspended in
2 mL of Tyrode’s buffer layered on 4 mL of 22.5% (wt/vol) Histo-
Denz density gradient medium (Sigma, St. Louis, MO), centrifuged
at ambient temperature for 15 minutes at 400g. Mast cells sedi-
mented at the bottom of the tube and were washed and suspended
in 2 mL of Tyrode’s buffer. After this protocol, mast cells repre-
sented 70% to 80% of the nucleated cells.
2.7. Mast cell degranulation assay
The release of b-hexosaminidase that parallels the release of
histamine was measured as an index of degranulation [36].
Degranulation of rat peritoneal cells (2.5  104 cells/well in 96-
well plates) was induced by stimulating these cells either with
substance P (30 lmol/L), A23187 (1 lmol/L) or compound 48/80
(10 lg/mL) in the presence of either cGMP (1, 5, 10 mmol/L) or
the cGMP degradation product 5’GMP (10 mmol/L) (triplicate
wells). Incubations were conducted in Tyrode’s buffer containing
0.1% BSA under gentle agitation for 45 minutes at 37C.
Culture supernatants were collected and transferred to a 96-
well plate. 100 lL of Triton X-100 solution (0.5%) was added to
the cells to quantify the enzyme activity remaining in the cells.
50 lL of either supernatant or Triton X-100 cell extracts were
transferred to a new 96-well plate and 100 lL of Tyrode’s buffer
was added to each well, followed by 50 lL substrate solution
(1.3 mg/mL p-nitrophenyl-N-acetyl-b-D-glucosamide in 0.04 mol/L
sodium citrate, pH 4.5). The plate was incubated at 37C for
120 minutes under gentle agitation. The reaction was stopped by
adding 20 lL of 1 mol/L glycine adjusted to pH 10.0 with NaOH,
and the absorbance at OD405nm (Optical density) of each well was
measured with a microplate reader. Mast cell degranulation (as a
percentage) was calculated by the following formula: % degranula-
tion = OD supernatant/(OD supernatant + OD pellet)  100.
2.8. Acetylcholine and electric ﬁeld stimulation of colonic tissues
Rat (Sprague-Dawley, male) colon tissue was divided into 2-cm
segments and transferred to a Schuler Organ Bath. Colon segments
were suspended in tissue bath vessels containing Krebs solution
(117.9 mmol/L NaCl, 4.7 mmol/L KCl, 25 mmol/L NaHCO3,
1.3 mmol/L NaH2PO4, 1.2 mmol/L MgSO4(H2O), 2.5 mmol/L CaCl2,
11.1 mmol/L D-glucose) continuously aerated with 95% O2, 5%
CO2 and maintained at a temperature of 37C. Tissue resting
tension was 0.5 g for electrical ﬁeld stimulation (EFS) studies and
1 g for ACh concentration-response curve studies. For EFS studies,
colonic tissues were stimulated at a ﬁxed frequency (8 Hz,
0.5-ms duration, 10 V, 3 trains of 10-second width, with a 2-min-
ute delay between trains). Two control stimulations were
performed, and tissues were allowed to recover for 10 minutes.
After the recovery period, tissues were treated with vehicle
(n = 10), uroguanylin (3 lmol/L) (n = 6), cGMP (1 mmol/L)
(n = 12), or 8-bromo-cGMP (100 lmol/L) (n = 5) at a volume of
100 lL, and EFS at the ﬁxed frequency was repeated. Contraction
amplitude is expressed as the percentage of baseline amplitude
of the second set of 8-Hz control stimulations. The amplitude of
stimulations before treatment is considered 100% amplitude.
Before measuring the effects of cGMP on ACh-stimulated contrac-
tions, an ACh concentration-response curve (n = 8, 10 nmol/L–
100 lmol/L) was performed. After a washing step and tissue
stabilization period, colon tissue segments were incubated with
either vehicle (n = 6) or cGMP (10–100 lmol/L) (n = 6), and the
ACh concentration-response curve was repeated. The maximumcontraction during the pretreatment concentration response curve
is considered the maximum (100%) response. Treatment with test
article was initiated 5 minutes before EFS or pharmacological stim-
ulation. Intracolonic instillation of TNBS, under isoﬂurane anesthe-
sia, in male Sprague-Dawley rats was performed as described in
the following.
2.9. Inﬂammation (TNBS)–induced colonic hypersensitivity
TNBS colitis in male Sprague-Dawley rats was induced as previ-
ously described [14]. Brieﬂy, under anesthesia with ketamine
(80 mg/kg, i.p.) and acepromazine (12 mg/kg, i.p.), rats received
either TNBS (50 mg/kg) or vehicle (1% methylcellulose, 0.9% saline)
administered in the proximal colon (1 cm from the cecum). Seven
days after TNBS administration, the number of abdominal contrac-
tions was measured in response to CRD by progressively inﬂating a
balloon (5 cm in length) inserted in the anus from 0 to 75 mm Hg,
each step of inﬂation lasting 30 seconds. Colonic thresholds were
determined by the pressure (mm Hg) required to elicit abdominal
contractions. To evaluate the ability of uroguanylin and cGMP to
modulate the hypersensitivity response, rats (n = 8 per group)
were orally administered either uroguanylin (3, 10, 30, 100,
300 lg/kg), cGMP (0.3, 3, 30 mg/kg), morphine (1 mg/kg), or vehi-
cle 30 minutes before CRD.
2.10. Myeloperoxidase activity in colon tissue
Colon tissue (100 mg wet weight, n = 8) was suspended in 1 mL
of buffer (0.5% hexadecyltrimethylammonium bromide in
10 mmol/L phosphate buffer, pH 6.0) and homogenized using Qia-
gen Tissue Lyser II. Homogenates were freeze-thawed 3 times to
disrupt the cells and were cleared by centrifugation at 13,000g at
4C. Myeloperoxidase (MPO) activity in the supernatants was as-
sayed by measuring the change in absorbance (460 nm) after
15 minutes resulting from the decomposition of H2O2 in the pres-
ence of O-dianisidine hydrochloride. The reactions (96-well format)
were carried out with 90 lL of 10 mM phosphate buffer, containing
0.2 mg/mL of O-dianisidine hydrochloride and 0.0006% of H2O2, and
started by the addition of 10 lL of tissue supernatant.
2.11. Acute partial restraint stress–induced colonic hypersensitivity
Partial restraint stress is a relatively mild, nonulcerogenic
model of restraint stress [54]. Under general anesthesia induced
by intraperitoneal administration of 0.6 mg/kg acepromazine
(Calmivet; Vetoquinol, Lure, France) and 120 mg/kg ketamine
(Imalgene 1000; Rhone Merieux, Lyon, France), 3 pairs of nichrome
electrodes were each implanted in the striated muscles of the
abdomen of female Wistar rats. The electrodes were exteriorized
on the back of the neck and protected by a glass tube attached to
the skin. Electromyography recordings were initiated 5 days after
surgery. The electrical activity of the abdominal striated muscle
was recorded with an electromyograph (Mini VIII; Alvar, Paris,
France) using a short time constant (0.03 seconds) to remove
low-frequency signals (<3 Hz) and a paper speed of 3.6 cm/min.
Brieﬂy, rats were lightly anesthetized with ethyl ether, and their
upper forelimbs and thoracic trunk were wrapped in a conﬁning
harness of paper tape to restrict but not prevent body movements
and placed in their home cages for 2 hours. Control sham-stress
animals were anesthetized but not wrapped in the conﬁning
harness. Colorectal distension was performed using a balloon in-
ﬂated from 0 to 60 mm Hg using increments of 15 mm Hg for
5 minutes each. Rats were accustomed to polypropylene tunnel de-
vices (diameter: 7 cm; length: 20 cm) during 5 days before the
start of CRD procedures to minimize recording artifacts caused
by movement of the animals. The balloon used for distension
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and ﬁxed at the base of the tail. The balloon, connected to a baro-
stat, was inﬂated progressively in increments of 5 minutes of
15 mm Hg each, ranging from 0 mmHg to 60 mmHg. Nonstressed
rats received either vehicle (2% dimethyl sulfoxide/15% b-cyclo-
dextrin in water) or cGMP (3 mg/kg) by gavage (n = 10 per group).
For the stress protocol, rats received CRD directly before and
15 minutes after 2 hours of restraint stress. Treatment groups of
rats (n = 8–12 per group) were administered either vehicle or
cGMP (3 mg/kg) by gavage 1.25 hours after the start of restraint
stress treatment, and CRD was performed 15 minutes after com-
pletion of the 2 hours of restraint stress.
2.12. Rat colonic mucosa transepithelial current and uroguanylin-
induced basolateral cGMP secretion
Proximal colons (n = 9) were collected frommale Sprague-Daw-
ley rats, and the seromuscular layers were removed by blunt dis-
section. Colonic tissue was mounted on slides with the 0.5-cm2
aperture. Three milliliters of Krebs bicarbonate Ringer solution
containing (in mM) 115 NaCl, 15 NaHCO3, 2.4 K2HPO4, 1.2 CaCl2,
1.2 MgCl2, and 0.4 KH2PO4 at pH 7.4 was added to the apical and
basolateral chambers of the Ussing chamber. The apical and baso-
lateral chambers also contained mannitol (10 mM) and glucose
(10 mM), respectively. The temperature in both chambers was
maintained constant at 37C, and Krebs bicarbonate Ringer solu-
tion was oxygenated throughout the experiment. Measurements
of transepithelial short-circuit current (Isc) were performed using
an automatic voltage clamp (Model VCC MC8; Physiologic Instru-
ments, San Diego, CA). At 0 minutes, 5 lL of vehicle (water) was
added to the apical chamber, followed by uroguanylin (1 lM) at
60 minutes. Aliquots of 100 lL were collected from the serosal
chamber every 15 minutes for analysis of secreted cGMP. Extracel-
lular cGMP was measured using the cGMP Biotrak (GE Healthcare,
Little Chalfont, UK) (Enzyme Immunoassay) System, and the rate of
cGMP secretion per surface area of tissue R [fmol/(min  cm2)] was
calculated using the equation: R = dC  V/A (where dC is the rate of
change in cGMP concentration, V is the volume of the Ussing
chamber [3 mL], A is the area of the slider aperture [0.5 cm2]).
2.13. Colitis-induced colonic afferent sensitization
To induce colitis, TNBS (30 mg per rat in vehicle [50% ethanol/
water]) was instilled with the rats under anesthesia (4% isoﬂurane)
via a transanal approachusingaPE-90catheterwhose tipwasplaced
approximately 6 cm proximal to the anus. As an added precaution,
Surgilube (Fougera, Melville, NY) was applied to the perineum to
minimize any potential contaminant irritation due to anal leakage.
This model of colitis is characterized by local areas of acute inﬂam-
mation peaking at 4 to 7 days, followed by a chronic, mononuclear
inﬂammatory cell inﬁltrate that persists up to 6 weeks until it re-
solveswithout spontaneous relapse. For themeasurement of colonic
afferent responses, female Sprague-Dawley rats were divided into 2
groups. In the ﬁrst group (n = 10), the responses of colonic afferents
to colonic distension were measured in control animals before and
after intraduodenal administration of cGMP (3 mg/kg in vehicle
[2% dimethyl sulfoxide/15% b-cyclodextrin in distilled water]). In
the second group (n = 11), the afferent responseswere tested in ani-
mals 8 to 10 days after TNBS-induced colitis, before and 20 to
30 minutes after intraduodenal administration of cGMP (3 mg/kg).
2.14. In vivo physiological instrumentation for afferent recording
studies
In vivo physiological instrumentation was performed with the
rats under urethane anesthesia (1.2 g/kg, s.c.). A latex balloon(10 mm wide and 30 mm long) was inserted through the anus
so that the tip of the balloon was 6 cm proximal to the anal verge.
The balloon was connected to a pressure transducer (World Preci-
sion Instruments, Sarasota, FL) and a syringe pump (Harvard Appa-
ratus, Holliston, MA) via 3-way stopcocks for ﬁlling and continuous
measurement of intracolonic pressure. A Transbridge transducer
ampliﬁer was used to amplify the signal from the pressure trans-
ducer, which was processed using a PowerLab 8s unit data acqui-
sition system (AD Instruments, Mountain View, CA) connected to
an Apple G5 computer [37,38].
2.15. Recording of nerve activity and identiﬁcation of afferent endings
The right pelvic nerve was isolated at the major pelvic ganglion,
dissected free from surrounding tissue, and cut at a maximal
distance from the ganglion. The cut end, still contiguous with the
colon, was positioned on a small platform and covered with
mineral oil. Fine bundles were dissected and placed on 1 arm of
a silver electrode, while a second arm was grounded. Impulses
were ampliﬁed (Grass QP511; Grass, West Warwick, RI) and
acquired with the PowerLab software as above and counted by a
rate meter in 1-second intervals. The rate meter threshold was
set to count potentials of desired amplitude. A bundle that had 1,
or at most 2, easily distinguishable active units was used. The affer-
ent ﬁring rate was calculated as the average number of impulses
per second over a 20-second period. Resting activity represented
maximal activity recorded 1 minute before each intervention.
Changes in afferent activity in response to interventions were
expressed as the percentage of change from the resting ﬁring rate.
Only afferents that clearly responded to inﬂation of the intracolon-
ic balloon were studied.
2.16. Mechanical testing of afferents
After identiﬁcation of the sensory ending, the mechanical sensi-
tivity of the afferent was tested by CRD with saline infusion to the
maximal pressure of 60 mm Hg. Afterward, the balloon was imme-
diately emptied and returned to a baseline pressure of 2 to
5 mm Hg. CRDs were repeated 2 to 3 times at 10- to 15-minute
intervals to ensure the stability of the responses. Afferent ﬁring
during CRD was averaged over 10-mm Hg increments of intraco-
lonic pressure.
2.17. Statistical analysis
The determination of statistical differences between groups was
determined by 1-way analysis of variance, and differences between
mean values were determined by Bonferroni correction post hoc
for multiple t tests. Statistical analysis of the number of abdominal
contractions obtained during 5-minute periods was performed by
analysis of variance using Student t test for paired or unpaired
values, as appropriate. A paired t test was used to compare the
responses of the same group of afferents before and after cGMP
administration. Unpaired t tests were performed to determine
statistically signiﬁcant differences in cGMP assays. All data are
expressed as the mean ± SEM. P < 0.05 is considered statistically
signiﬁcant.
3. Results
3.1. Uroguanylin reduces inﬂammation (TNBS)-induced colonic
hypersensitivity
The pharmacological effects of the synthetic GC-C peptide
agonist linaclotide in signiﬁcantly reducing colonic hyperalgesia
in models of inﬂammation- and stress-induced visceral
Fig. 2. Effects of uroguanylin on myeloperoxidase (MPO) activity in the inﬂamed rat
proximal colon and in the noninﬂamed distal colon. Colonic tissues were homog-
enized, and MPO activity in cleared supernatants was measured after 15 minutes by
the change in absorbance (460 nm) resulting from the decomposition of H2O2 in the
presence of 0.2 mg/mL O-dianisidine hydrochloride. MPO activity is expressed in
units per milligram of colon tissue. All data are expressed as the mean ± SEM (n = 8).
⁄P = 0.03 versus vehicle-treated group, distal colon.
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endogenous hormone uroguanylin elicits similar effects on colonic
hyperalgesia in a rat TNBS inﬂammation model. Oral administra-
tion of uroguanylin at doses of 30, 100, and 300 lg/kg before
CRD resulted in dose-dependent, signiﬁcantly (P < 0.01, 100 and
300 lg/kg) increased colonic thresholds required to elicit abdomi-
nal contractions compared with TNBS vehicle–treated animals
(Fig. 1). In addition, the colonic thresholds at the 100 and 300-
lg/kg dose levels were not signiﬁcantly different from those of
naive animals (Fig. 1). Increased colonic thresholds were also
observed after orally administered uroguanylin at doses of 3 and
10 lg/kg, but were not statistically signiﬁcant (data not shown).
Animals treated with a subcutaneous dose of morphine (1 mg/
kg), were used as positive controls, as previously described [14]
(Fig. 1). MPO activity as a marker of tissue inﬂammation was sig-
niﬁcantly (P < 0.05) increased only in the proximal colon (site of
TNBS instillation), but not in the noninﬂamed distal colon
(P = 0.03 between vehicle groups) (Fig. 2). Orally administered
uroguanylin at all dose levels elicited no signiﬁcant effects on
MPO activity either in the noninﬂamed distal colon or under
inﬂammatory conditions in the proximal colon when measured 3
hours after dosing (Fig. 2).
3.2. Expression of GC-C, guanylin, and uroguanylin in rat small and
large intestine
GC-C is predominantly expressed in the intestine, and activa-
tion of GC-C accounts for the primary source of cGMP in intestinal
epithelial cells [9,21,29,39,47]. In the rat intestinal tract, high
levels of GC-C mRNA expression were detected in all regions,
especially in the jejunum, cecum, and ascending and transverse
colon (Supplemental Fig. 1A). Similarly, expression of guanylin
and uroguanylin was detected in all regions of the rat intestine
(Supplemental Figs. 1B and 1C). In TNBS-treated rats, GC-C
expression was decreased in the proximal colon (site of TNBS
administration) compared with the distal colon. Uroguanylin at
all dose levels had no effect on GC-C expression in either region
of the colon (data not shown). We further investigated GC-C
expression in a broad panel of nonintestinal tissues including
dorsal root ganglia neurons in naive rats. No detectable levels of
GC-C, guanylin, and uroguanylin expression were found in most
nonintestinal tissues, including dorsal root ganglion neurons
(Supplemental Figs. 1A–C).Fig. 1. Effects of uroguanylin on inﬂammation-induced colonic hypersensitivity in
rats. Inﬂammatory colitis in rats (n = 8 per group) was induced by intracolonic
instillation of trinitrobenzene sulfonic acid (TNBS) (50 mg/kg), and colonic thresh-
olds required to elicit abdominal contractions were determined in response to
graded colorectal distension 7 days after TNBS treatment. Uroguanylin (30, 100,
300 lg/kg) and vehicle were orally administered 30 minutes before colorectal
distension. Data are expressed as the mean ± SEM. ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001 versus
vehicle-treated animals (1-way analysis of variance, followed by Bonferroni
correction post hoc for multiple t tests).3.3. Effects of uroguanylin on intracellular accumulation of cGMP and
on apical and basolateral transport of cGMP from Caco-2 cells
Ligand binding of GC-C agonists stimulates the intrinsic guany-
late cyclase activity of the receptor, resulting in the conversion of
guanosine-50-triphosphate to cGMP and increased intracellular
concentrations of this signaling molecule [21]. As shown in
Fig. 3A, exposure of human colorectal adenocarcinoma Caco-2
cells, a commonly used model system for intestinal epithelium
[45] that express GC-C (data not shown) [52], to the endogenous
hormone uroguanylin increased intracellular concentrations of
cGMP. Incubation of Caco-2 cells with uroguanylin in the presence
of probenecid, a pharmacological inhibitor of the cGMP transport-
ers MRP4 and MRP5 and the solute carrier (SLC) family member
OAT2, did not affect intracellular cGMP concentrations (Fig. 3A).
We then investigated whether increased intracellular cGMP
concentrations in Caco-2 cells after uroguanylin activation of
GC-C are associated with extracellular cGMP transport into the api-
cal and basolateral compartments. As shown in Fig. 3B and C, expo-
sure of Caco-2 cells to uroguanylin resulted in the concomitant
transport of cGMP into the apical and basolateral compartments,
respectively, with apical cGMP concentrations 7- to 8-fold in-
creased over basolateral concentrations. Both apical and basolat-
eral export of cGMP was signiﬁcantly inhibited in the presence of
probenecid in a concentration-dependent manner (Fig. 3B and C),
indicative of active cGMP transport out of Caco-2 cells. To further
conﬁrm the involvement of active cGMP transport processes,
unstimulated Caco-2 cells were incubated with either 200 nM or
1 lM cGMP added to the apical compartment, in the presence or
absence of probenecid. Under those conditions, no measurable
amounts of cGMP were found in the basolateral compartment
(data not shown).
3.4. Expression of MRP4, MRP5, and OAT2 transporters in Caco-2 cells
and in the rat small and large intestine
Previous studies investigating MRP4, MRP5, and OAT2 expres-
sion in Caco-2 cells and in different regions of the human intestine
found either low or nondetectable levels of these transporters
[20,32,41,48,53]. We conﬁrm these ﬁndings, but show that their
Fig. 3. Uroguanylin activation of guanylate cyclase-C on Caco-2 cells: effects on intracellular cyclic guanosine-30 ,50-monophosphate (cGMP) production and on apical and
basolateral cGMP transport. Conﬂuent Caco-2 cell monolayers (day 21), conﬁrmed by transepithelial electric resistance measurement, were preincubated with probenecid
(0.5 and 2 mmol/L) for 15 minutes, followed by incubation either with vehicle, uroguanylin (1 lmol/L), or uroguanylin (1 lmol/L) plus probenecid (0.5 and 2 mmol/L) for
60 minutes (n = 3). Intracellular cGMP concentrations (A) and cGMP concentrations in the apical (B) and basolateral compartments (C) were determined by liquid
chromatography coupled to mass spectrometry (LC/MS/MS) analysis, derived from a cGMP standard curve. The amount of cGMP indicates the total amount of cGMP
recovered from each compartment. The limit of quantitation in this assay is 0.05 pmol/mL. Data are expressed as the mean ± SEM. ⁄P < 0.05, ⁄⁄P < 0.01 versus uroguanylin-
treated cells.
Fig. 4. Effects of cyclic guanosine-30 ,50-monophosphate (cGMP) on inﬂammation-
induced colonic hypersensitivity in rats. Inﬂammatory colitis in rats (n = 7–8 per
group) was induced by intracolonic instillation of trinitrobenzene sulfonic acid
(TNBS) (50 mg/kg), and colonic thresholds required to elicit abdominal contractions
were determined in response to graded colorectal distension 7 days after TNBS
treatment. cGMP (0.3, 3, 30 mg/kg) and vehicle were orally administered 30 min-
utes before colorectal distension. Data are expressed as the mean ± SEM. ⁄⁄P < 0.01,
⁄⁄⁄P < 0.001 versus vehicle-treated animals (1-way analysis of variance, followed by
Bonferroni correction post hoc for multiple t tests).
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der:MRP4 > MRP5 > OAT2 (Supplemental Fig. 2A, insert). To explore
whether similar mechanisms of cGMP transport could occur in vivo
in the rat intestinal tract, we measured the expression of MRP4,
MRP5, and OAT2 in segments of the rat intestine ranging from the
duodenum to the rectum. In general, we found only low levels of
MRP4 expression (Supplemental Fig. 2A), whereasMRP5 expression
levels were markedly elevated in the colon compared with MRP4
(Supplemental Fig. 2B). Similarly, expression of MRP4 and MRP5
was found inmucosal tissue extruded from each region of the intes-
tine (data not shown). OAT2 expressionwas generally belowdetect-
able threshold levels (data not shown). The rank order of cGMP
transporter expression in the rat intestine (MRP5 > MRP4 > OAT2)
was different from that of Caco-2 cells. In TNBS-treated rats, MRP4
and MRP5 expression levels were neither altered in the inﬂamed
proximal colonnor in thenoninﬂameddistal colon. Similarly, urogu-
anylin at all dose levels had no effect onMRP4 andMRP5 expression
in either region of the colon (data not shown).
3.5. cGMP reduces inﬂammation (TNBS)-induced colonic
hypersensitivity
We then asked whether the effects of uroguanylin in the TNBS-
induced model of colonic hypersensitivity to distension could be
mimicked by the primary downstream effector of uroguanylin,
cGMP. Oral administration of cGMP at doses of 0.3, 3, and 30 mg/
kg 30 minutes before CRD signiﬁcantly (P < 0.01, 3 mg/kg;
P < 0.001, 30 mg/kg) and dose dependently increased colonic
thresholds in this model compared with vehicle-treated animals
(Fig. 4). In addition, the colonic threshold after an oral dose of
30 mg/kg cGMP was not signiﬁcantly different from that of naive
animals (Fig. 4). Animals treated with a subcutaneous dose ofmorphine (1 mg/kg) were used as positive controls, as previously
described [14] (Fig. 4).
3.6. cGMP reduces acute restraint stress–induced colonic
hypersensitivity
We then assessed whether cGMP also elicits analgesic effects in
a mechanistically different model of colonic hypersensitivity, using
a nonulcerogenic mild restraint stress (wrap restraint) model. Oral
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with high stress responsiveness, had no signiﬁcant effect on colo-
rectal sensitivity to distension under basal conditions (sham stress)
when compared with vehicle-treated animals (data not shown).
After 2 hours of restraint stress, the number of abdominal contrac-
tions in vehicle-treated rats was signiﬁcantly (P < 0.05) increased
at all distension pressures tested compared with sham-stressed
animals (Fig. 5). Orally administered cGMP (3 mg/kg) signiﬁcantly
(P < 0.05) reduced stress-induced visceral hypersensitivity at all
distension pressures tested, without affecting colonic volumes
(Fig. 5 and data not shown).
3.7. cGMP decreases colonic afferent ﬁring rates in response to colonic
distension in rats
Because visceral afferent sensitization is thought to play a key
role in IBS symptoms of abdominal pain and discomfort, we
assessed the analgesic effects of cGMP in a model of TNBS-induced
colonic afferent sensitization, using single-unit colonic afferent
recordings. Before colonic irritation, incremental colonic distension
led to incremental increases in colonic afferent ﬁring. cGMP,
administered intraduodenally at a dose of 3 mg/kg, had no signiﬁ-
cant effect on afferent ﬁring rates during colonic distension in con-
trol animals at intracolonic pressures of 10 to 50 mm Hg, but
signiﬁcantly decreased afferent ﬁring rates (50%) at 60 mm Hg
(noxious range) (P < 0.05). In the 40- to 50-mm Hg distension
range (suprathreshold, subnoxious), a nonsigniﬁcant downward
trend in afferent ﬁring was observed in the cGMP-treated animals
(data not shown). In animals with subacute colitis, 8 to 10 days
after intrarectal instillation of TNBS, incremental CRD led to signif-
icant incremental increases in colonic afferent ﬁring rates. cGMP,
intraduodenally administered at a dose of 3 mg/kg, signiﬁcantly
(P < 0.05) decreased colonic afferent ﬁring rates in response to
colonic distension at distension pressures ranging from 30 to
60 mm Hg (pressure range of C-ﬁber afferents) compared with
their responses to distension before cGMP administration (Fig. 6).
3.8. Uroguanylin stimulates cGMP secretion from the basolateral
surface of rat colonic mucosa
Because exogenous cGMP signiﬁcantly decreased colonic
afferent ﬁring rates in response to colonic distension, we investi-
gated whether uroguanylin, through activation of the GC-C/cGMPFig. 5. Effects of cyclic guanosine-30 ,50-monophosphate (cGMP) on stress-induced
colonic hypersensitivity in rats. The animals (n = 9–10 per group) were subjected
for 2 hours to partial restraint stress and received either orally dosed vehicle
(n = 12) or cGMP (3 mg/kg) (n = 8) 1.25 hours after the initiation of restraint stress.
Sham-stressed rats were treated orally with vehicle (n = 12). Abdominal contrac-
tions in response to graded colorectal distension were determined 15 minutes after
completion of 2 hours of restraint stress treatment. Data are expressed as the
mean ± SEM. ⁄P < 0.05 versus vehicle-treated animals, +P < 0.05 versus sham stress-
treated animals.pathway could stimulate the secretion of cGMP into the rat colon
submucosa, using an ex vivo Ussing chamber assay. Ion transport
and epithelial barrier function were monitored by measuring Isc
and transepithelial electrical resistance. Uroguanylin stimulation
(1 lM) elicited a robust Isc across rat colonic epithelium (Fig. 7A),
which reached a maximum within 10 minutes after stimulation
and remained constant until the end of the study. The secretion
of cGMP into the chamber exposed to the basolateral side of the co-
lonic epithelium was measured before and after the addition of
uroguanylin. In this assay, the basal rate of cGMP secretion was
5.46 fmol/min  cm2. Exposure of rat colonic mucosa to uroguany-
lin resulted in an approximately 6-fold increased cGMP secretion
from the basolateral side of the epithelium, with a calculated rate
of cGMP secretion of 32.34 fmol/min  cm2 (Fig. 7B). The transepi-
thelial electrical resistance of the colonic mucosa remained high
during the course of the study, indicating that the diffusion barrier
for cGMP between apical and basolateral sides remained intact
throughout the study (data not shown).
3.9. cGMP has no effect on rat peritoneal mast cell degranulation
Intestinalmucosalmast cells are located in close proximity to affer-
ent ﬁbers in the mucosa and have been implicated in the pathophysi-
ology of IBS [1,2]. We used rat peritoneal mast cells to further
investigate whether the pharmacological effects of cGMP, observed
in vivo in a rat model of postinﬂammatory visceral hyperalgesia, are
linked to a mechanism associated with the inhibition of mast cell
degranulation. Measurement of b-hexoaminidase release, a marker
of mast cell degranulation, after incubation of peritoneal mast cells
with substance P, the calcium ionophore A23187, or compound
48/80 conﬁrmed the ability of these agents to potently stimulate their
degranulation (Supplemental Figs. 3A–C). When rat peritoneal mast
cells were stimulated with these agents in the presence of increasing
concentrations of cGMP (1–10mmol/L), no effects on mast cell
degranulationwereobserved (Supplemental Figs. 3A–C). Furthermore,
cGMP alone did not modulate degranulation of vehicle-treated mast
cells. Similarly, the cGMP degradation product 50-GMP (10mmol/L)
had no effect on either substance P–, A-23187-, or compound 48/80–
stimulatedmast cell degranulation, nor did 50-GMPmodulate degran-
ulation of vehicle-treated mast cells (data not shown).
3.10. cGMP has no effect on EFS and ACh-induced contractions of rat
colonic tissue
Next, we investigated whether the antihyperalgesic effects of
cGMP in vivo in ratmodels of after inﬂammatory and stress-inducedFig. 6. Effects of cyclic guanosine-30 ,50-monophosphate (cGMP) on colonic afferent
ﬁring rates in trinitrobenzene sulfonic acid (TNBS)–sensitized rats. Colonic single-
unit afferent responses to graded colorectal distension in rats 10 days after
intracolonic instillation of TNBS (30 mg per rat), treated intraduodenally either
with vehicle (n = 11) or cGMP (3 mg/kg) (n = 11). Data are expressed as the
mean ± SEM. ⁄P < 0.05 versus vehicle-treated animals.
Fig. 7. Effects of uroguanylin on transepithelial short-circuit current and cyclic guanosine-30 ,50-monophosphate (cGMP) secretion from the basolateral side of rat colonic
mucosa. Vehicle and uroguanylin (1 lM) were added to the apical chamber of the Ussing chamber at time 0 and 60 minutes, respectively. Treatment with uroguanylin elicited
a robust transepithelial short-circuit current (A) and increased secretion of cGMP from the basolateral side of the rat colonic mucosa (B). Data (n = 9) are presented as
mean ± SEM.
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smooth muscle contractility. In vitro, neither cGMP (1 mmol/L)
nor uroguanylin (3 lmol/L) attenuated EFS-induced contractions
of rat colonic tissue (Fig. 8A); in contrast, membrane-permeable
8-bromo-cGMP (100 lmol/L) signiﬁcantly (P < 0.01) reduced EFS-
induced contractions of colonic tissue (Fig. 8A). The EC50 for ACh-
induced colonic contractions in the presence of 100 lmol/L cGMP
(550 nmol/L) were similar to the EC50 for vehicle (340 nmol/L), indi-
cating no functionally relevant difference (Fig. 8B). We then as-
sessed the potential effects of uroguanylin on smooth muscle
contractility in inﬂamed rat colonic segments, 7 days after intraco-
lonic instillation of TNBS. Similar to colonic tissue in naive rats,
uroguanylin (3 lmol/L) did not attenuate EFS-induced contractions
in inﬂamed colonic tissue (Supplemental Fig. 4). 8-Bromo-cGMP
(100 lmol/L) signiﬁcantly reduced EFS-induced contractions
(P < 0.05); however, this effect was markedly less pronounced than
the signiﬁcant decrease (P < 0.001) in EFS-induced contractions ob-
served in colonic tissue from naive rats (Supplemental Fig. 4).4. Discussion
We provide evidence that activation of intestinal GC-C by
uroguanylin reduces colonic hypersensitivity and, importantly,Fig. 8. Effects of cyclic guanosine-30 ,50-monophosphate (cGMP) on electric ﬁeld stimulat
tissue segments (2 cm) were suspended in tissue bath vessels containing Krebs solution a
were induced by electric ﬁeld EFS at a ﬁxed frequency (8 Hz, 0.5 ms, 10 V, 3 trains of 10
after 2 control stimulations, colonic tissues were incubated with vehicle (n = 10), cGMP (
(n = 5) for 5 minutes before EFS at the ﬁxed frequency. Contraction amplitude is expr
stimulations. (B) After stabilization after a control acetylcholine (ACh) concentration-r
5 minutes either with vehicle (n = 6) or cGMP (100 lmol/L) (n = 6) before repeating the
concentration response curve is considered the maximum (100%) response. Data are exthat these analgesic effects of uroguanylin are mimicked by cGMP,
the primary GC-C downstream effector in several models of colonic
hypersensitivity. These data reveal a novel, previously unrecog-
nized mechanism linking the GC-C/cGMP pathway to the modula-
tion of gastrointestinal pain (Fig. 9).
The function of uroguanylin as an intestinal secretagogue via
activation of the GC-C/cGMP pathway in intestinal epithelial cells
has been ﬁrmly established [15,23]. Thus, the GC-C/cGMP pathway
is considered the principal regulator of intestinal ﬂuid homeosta-
sis. Additionally, GC-C signaling plays important roles in the resto-
ration of mucosal barrier function in intestinal disorders and
homeostatic control of the intestinal crypt-villus axis [18,28].
Moreover, recent ﬁndings that linaclotide, a selective GC-C agonist
peptide acting locally within the gastrointestinal tract, decreased
colonic hypersensitivity in models of inﬂammatory and stress-in-
duced visceral hypersensitivity, has for the ﬁrst time implicated
GC-C in regulation of visceral pain [16]. Furthermore, in 2 phase
3 clinical trials, linaclotide signiﬁcantly improved abdominal pain
in patients with IBS-C (13,42). These ﬁndings prompted us to fur-
ther investigate whether the modulation of colonic hypersensitiv-
ity after uroguanylin activation of GC-C in the gastrointestinal tract
may have evolved as a function not previously linked to the GC-C/
cGMP pathway and whether these effects of uroguanylin are mech-
anistically linked to the primary GC-C downstream effector, cGMP.ion (EFS)– and acetylcholine-induced contractions of rat colonic tissues. Rat colonic
nd continuously aerated with 95% O2, 5% CO2 at 37C. (A) Colonic tissue contractions
-second width, with a 2-minute delay between trains). After a 10-minute recovery
1 mmol/L) (n = 12), uroguanylin (3 lmol/L) (n = 6), or 8-bromo-cGMP (100 lmol/L)
essed as the percentage of baseline amplitude of the second set of 8-Hz control
esponse curve (10 nmol/L–100 lmol/L) (n = 8), colonic tissues were incubated for
ACh concentration-response curve. Maximum contraction during the pretreatment
pressed as the mean ± SEM. ⁄⁄⁄P < 0.001.
Fig. 9. Proposed mechanism of action of guanylate cyclase-C (GC-C) agonists, through activation of the GC-C/cyclic guanosine-30 ,50-monophosphate (cGMP) pathway, as
gastrointestinal analgesics. 1. GC-C agonists bind and activate GC-C at the apical surface of intestinal epithelial cells, the location of GC-C expression. 2. Activation of GC-C
results in hydrolysis of guanosine triphosphate (GTP) and production of cGMP inside the epithelial cells. 3. Intracellular cGMP is actively transported out of epithelial cells by
efﬂux pumps into the submucosa. 4. Extracellular cGMP is proposed to inhibit colonic nociceptors.
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cellular transport of cGMP. Exposure of human Caco-2 cells to
uroguanylin led to increased cGMP concentrations in the apical
and basolateral compartments, with higher cGMP concentrations
found on the apical side. Because cell membranes are virtually
impermeable to cyclic nucleotides such as cGMP, requiring en-
ergy-dependent transport, we measured the expression of known
cGMP transporters in Caco-2 cells and in a panel of rat intestinal
tissues. Consistent with previous reports, we found that expression
of MRP4 in Caco-2 cells, a transporter localized predominantly in
the apical membrane, is higher than that of MRP5, which is local-
ized predominantly in the basolateral membrane. Together, these
ﬁndings most likely account for the observed differences in apical
and basolateral cGMP concentrations. Incubation of Caco-2 cells
with uroguanylin in the presence of probenecid inhibited cGMP ex-
port in a concentration-dependent fashion, conﬁrming the involve-
ment of active transport mechanisms in this process. In contrast to
Caco-2 cells, we found greater expression of MRP5 compared with
MRP4 in all regions of the rat small and large bowel, suggesting in-
creased cGMP transport in vivo into the submucosal space. The
expression of MRP4 and MRP5 was generally greater in the colon
compared with the small intestine, a pattern similar to that ob-
served in the human intestine [55]. When we measured intracellu-
lar cGMP concentrations in Caco-2 cells after exposure to
uroguanylin in the presence of probenecid, we detected no signif-
icant elevation of cGMP in these cells, as previously reported [53].
The activity of cGMP-binding phosphodiesterases is considered the
major cGMP elimination pathway controlling cellular cGMP levels.
However, MRP4 and MRP5 have been characterized as overﬂow
pumps, supporting the decrease in intracellular cGMP levels under
conditions in which cGMP synthesis is strongly induced and,
importantly, providing extracellular cyclic nucleotides for possible
paracrine actions [43,55].
The synthetic GC-C agonist linaclotide is an orally administered,
minimally absorbed peptide eliciting its effects locally in the
gastrointestinal tract, and is closely related to the cGMP-regulating
hormone uroguanylin [7,8]. Linaclotide potently decreases colonic
hypersensitivity in several models of visceral pain in aGC-C-dependent manner, leading us to investigate the effects of
an endogenous GC-C agonist, uroguanylin, on modulating gastroin-
testinal pain [16]. In a model of inﬂammation-induced colonic
hypersensitivity, orally administered uroguanylin decreased colo-
nic hyperalgesia, as evidenced by increased colonic thresholds re-
quired to elicit abdominal muscle contractions during CRD,
suggesting that the modulation of colonic sensation may have
evolved as a previously unrecognized effect of GC-C agonism in
intestinal epithelial cells. Although the role of cGMP and its mech-
anism in the regulation of intestinal ﬂuid homeostasis is ﬁrmly
established, no role of non-neuronal cGMP in modulating gastroin-
testinal pain has been previously reported. Thus, we investigated
whether the analgesic effects of uroguanylin could be mimicked
by the GC-C downstream effector cGMP. In several mechanistically
different models of gastrointestinal pain, orally administered cGMP
signiﬁcantly decreased visceral hypersensitivity. Together, these
results have uncovered a novel role of an endogenous GC-C agonist,
uroguanylin, in the peripheral modulation of gastrointestinal sen-
sation, effects mimicked in vivo by cGMP and providing a strong
rationale for targeting the GC-C/cGMP pathway for treatment of
functional gastrointestinal disorders characterized by abdominal
pain, such as IBS-C.
Although the pathophysiology of IBS is not completely under-
stood, immunological, psychological, genetic, microbial, visceral
nociceptive, motility, and mast cell factors may all be involved
[1,2,19,24]. When we studied the effects of uroguanylin and cGMP
on colonic contractility in naive and TNBS-treated rats in response
to ACh or EFS as a potential mechanism mediating inhibition of co-
lonic visceral pain, we did not observe any effect on the GC-C/
cGMP pathway, indicating that this pathway neither affects colonic
contractility nor has spasmolytic activity.
Several lines of evidence from both animal models and clinical
studies appear to support a mechanistic role of colonic mast cells
in the pathogenesis of visceral hypersensitivity and generation of
abdominal discomfort and pain associated with IBS [1,2,26,34,35].
However, their role in this condition remains controversial [5,50].
When we investigated the pharmacological effects of cGMP on
modulating the release of mast cell–speciﬁc mediators from rat
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ophore A23187, or compound 40/80, we found that cGMP had no
effect on mast cell degranulation, consistent with previously re-
ported data that the cyclic nucleotides cGMP and cyclic adenosine
monophosphate did not affect the release of histamine from
activated rat mast cells [49]. These ﬁndings suggest that the
cGMP-mediated decrease of colonic hypersensitivity observed in
our animal models of gastrointestinal pain is not directly associated
with modulating the release of mast cell mediators.
Visceral sensory afferents modulate their ﬁring properties in re-
sponse to the local environment in both normal and pathological
conditions. During disease states such as chronic visceral pain,
chronic changes in afferent pathways (sensitization) lead to persis-
tently enhanced perceptions of noxious stimuli responses to nor-
mally non-noxious stimuli. Because second-order neurons in the
CNS have been shown to receive convergent input from different
visceral organs, it has been suggested that this mechanism under-
lies viscerosomatic and viscerovisceral (cross-organ) referral and
sensitization [37,38]. Such sensitization pathway changes are con-
sidered a central process in the development of chronic visceral
pain, and such changes can be measured in primary colonic affer-
ent nerve terminals (peripheral sensitization). The development of
altered mechano- and chemosensitive properties of primary colo-
nic afferents is likely a critical step in the transmission of painful
stimuli to the CNS. Thus, primary colonic afferents are potential
targets for visceral pain because they directly link the gastrointes-
tinal tract to the CNS. Several ion channels and receptors expressed
on terminals of visceral primary afferent neurons are currently un-
der investigation as potential targets for visceral pain therapy
[3,4,6]. Because cGMP elicits potent analgesic effects in several
models of gastrointestinal pain, we hypothesize that cGMP may
act on intestinal afferent ﬁbers while traveling along the small
intestine, the projections of which converge on second-order neu-
rons that also receive input from colonic afferents, thus affecting
their function. This is consistent with our ﬁndings that cGMP
concentrations needed to potentially modulate afferent nerve
ﬁring are present in the extracellular mucosal space of the duode-
num, jejunum, and ileum (Supplemental Table 1). In addition, we
investigated whether in a TNBS model of experimental colitis,
cGMP affects colonic afferent sensitization and found that cGMP
signiﬁcantly decreased the ﬁring rates of sensitized pelvic afferent
neurons in response to mechanical stimuli. Moreover, we recently
showed, using an in vitro preparation, that both cGMP and urogu-
anylin decrease the mechanosensitivity of high-threshold colonic
afferent from both splanchnic and pelvic nerves [10,11], as well
as the responses of control and sensitized muscular and muscu-
lar-mucosal afferents to stretch (Feng et al, accepted for publica-
tion). In addition, using ex vivo Ussing chamber assays,
uroguanylin stimulates cGMP secretion in the colonic submucosa.
These results uncover a previously undescribed function of cGMP
in modulating gastrointestinal pain and further provide a strong
rationale for targeting the GC-C/cGMP pathway for the treatment
of functional gastrointestinal disorders characterized by symptoms
of abdominal pain, such as IBS-C.
4.1. Conclusions
These studies have demonstrated that uroguanylin activation of
the GC-C/cGMP pathway increases extracellular transport of cGMP
and signiﬁcantly decreases colonic hypersensitivity. The analgesic
effects of uroguanylin are mimicked in vivo by its primary down-
stream effector cGMP, suggesting that cGMP is the primary medi-
ator in this process and that regulation of visceral sensory signaling
has evolved as a physiological function not previously linked to the
GC-C/cGMP pathway. Moreover, the translational concept of ther-
apeutically targeting the GC-C/cGMP pathway for the treatment ofgastrointestinal pain has now been validated in the clinic. Phase 2b
and 3 trials conducted in IBS-C patients have conﬁrmed that linacl-
otide improves the deﬁning symptoms of this disease—abdominal
pain and discomfort in addition to constipation symptoms
[13,22,42].
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